Vaxil Bio Ltd
Research Vaxil Bio Ltd (VXL) on Bullrun: market cap CAD 577.68K, P/E 1.0. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerVXL
- ExchangeV
- CountryCanada
- SectorHealthcare
- IndustryBiotechnology
- CurrencyCAD
- Market capCAD 577.68K
- P/E1.0
- Financial periodQ1 2026
- RevenueCAD 0
- Net income-CAD 107.00K
- Free cash flow-CAD 144.00K
Valuation Snapshot
latest market cap is CAD 577.68K; P/E is 1.0.
Peer valuation comparison
Latest P/E is 0.97x versus a Healthcare sector median of 24.67x (96.1% below).
Latest P/E is 0.97x versus a Canada median of 15x (93.6% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CAD 0 | CAD 522.00K | -CAD 158.00K | n/a | n/a | CAD 671.00K | n/a | CAD 1.37M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-02 | CAD 577.68K | 1.0 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 CAD.
About Vaxil Bio Ltd
Vaxil Bio Ltd., a biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. The company is headquartered in Toronto, Canada.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Vaxil Bio Ltd's market cap?
Vaxil Bio Ltd's market capitalization is CAD 577.68K.
What is Vaxil Bio Ltd's P/E ratio?
Vaxil Bio Ltd's price-to-earnings (P/E) ratio is 1.0.
What does Vaxil Bio Ltd do?
Vaxil Bio Ltd., a biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. The company is headquartered in Toronto, Canada.